US Patent

US6794410 — Use of (Z)-2-cyano-3-hydroxy-but-2-enoic acid-(4â²-trifluoromethylphenyl)-amide for treating multiple sclerosis

Method of Use · Assigned to Aventis Pharmaceuticals Inc · Expires 2026-09-12 · 0y remaining

Vulnerability score 85/100 Vulnerable — likely target for IPR or design-around

What this patent protects

This patent protects the use of a specific compound for treating the symptoms of multiple sclerosis.

USPTO Abstract

The invention relates to the use of compound of Formula I in treating patients for the symptoms of multiple sclerosis.

Drugs covered by this patent

Aubagio (TERIFLUNOMIDE) · Sanofi

FDA Patent Use Codes

When a patent is method-of-use, FDA lists it once per applicable indication ("U-code"). Each U-code carves out a specific therapeutic use that generic filers must either license or design around.

Code	Description	Drug
`U-1285`	—	Aubagio
`U-1285`	—	Aubagio

Patent Metadata

Patent number: US6794410
Jurisdiction: US
Classification: Method of Use
Expires: 2026-09-12
Drug substance claim: No
Drug product claim: No
Assignee: Aventis Pharmaceuticals Inc
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.